drugset / Trial / NCT01140672

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

NCT01140672

Phase 1 Completed 48 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

The goals of this study are to evaluate the safety and tolerability of multiple ascending doses of PF-04634817 administered orally to healthy adult subjects. In additional, the plasma and urinary pharmacokinetics of multiple ascending doses of PF-04634817 administered orally to healthy adult subjects will be evaluated. Finally, the effect of multiple doses of PF-04634817 on circulating monocytes will be explored.

Timeline

Start
2010-06
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04634817 Small molecule 3 mg Oral
Subject PF-04634817 Small molecule 30 mg Oral
Subject PF-04634817 Small molecule 100 mg Oral
Subject PF-04634817 Small molecule 300 mg Oral

Indications

No indication recorded.